Tecan Group (TCHBF) Stock Price, News & Analysis

Company Overview

Tecan Group AG (OTCMKTS:TCHBF) is a Switzerland-based life sciences company specializing in the development, manufacturing and distribution of automated laboratory instruments and solutions. Its core business centers on liquid-handling workstations, detection and analysis technologies, and integrated workflow platforms designed to streamline research and development, quality control and diagnostic applications. Tecan’s products serve customers in the biopharmaceutical, biotechnology and clinical diagnostics sectors, as well as academic and government laboratories engaged in genomics, proteomics and pharmaceutical screening.

Founded in 1980 and headquartered in Männedorf, Switzerland, Tecan has grown from a regional instrument supplier into a global provider with a presence in more than 50 countries. Over the years, the company has expanded through targeted acquisitions and strategic partnerships, establishing manufacturing facilities in Europe, North America and Asia–Pacific. This global footprint allows Tecan to support its customers with localized service, application expertise and regulatory compliance in key markets worldwide.

Tecan’s comprehensive product portfolio includes bench-top liquid handling systems, high-throughput screening platforms, microplate readers and integrated workflow solutions. These instruments are complemented by tailored reagents, assays and software that enable automated sample preparation, assay development and data analysis. The company’s offerings are widely used in drug discovery, immunoassays, next-generation sequencing, cell biology and molecular diagnostics, helping researchers and clinicians achieve higher throughput, reproducibility and cost efficiency.

The company is guided by a seasoned executive management team and overseen by a board of directors committed to innovation and sustainable growth. Under the leadership of CEO Jürg Wild, Tecan continues to invest in research and development, expand its application support capabilities and pursue geographic diversification. This leadership framework positions Tecan to meet evolving customer needs and to capitalize on emerging trends in personalized medicine, precision diagnostics and life sciences research.

Key Stats

• Today's Range: $211.90 to $211.90
• 50-Day Range: $191.11 to $211.90
• 52-Week Range: $182.45 to $340.27
• Volume: N/A
• Average Volume: 1,101 shs
• Market Capitalization: N/A
• P/E Ratio: 49.62
• Dividend Yield: 0.71%
• Price Target: N/A
• Consensus Rating: N/A

Tecan Group Stock Analysis - MarketRank™

Tecan Group scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Tecan Group.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Tecan Group is 49.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tecan Group is 49.62, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.26.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Tecan Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tecan Group has recently increased by 27.97%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Tecan Group is a leading dividend payer. It pays a dividend yield of 4.42%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Tecan Group does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Tecan Group is 35.13%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Tecan Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tecan Group has recently increased by 27.97%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for TCHBF on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tecan Group insiders have not sold or bought any company stock.

Percentage Held by Institutions

46.80% of the stock of Tecan Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TCHBF Stock Analysis - Frequently Asked Questions

How have TCHBF shares performed this year?

Tecan Group's stock was trading at $208.03 on January 1st, 2025. Since then, TCHBF shares have increased by 1.9% and is now trading at $211.8974.

How do I buy shares of Tecan Group?

Shares of TCHBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/20/2025
• Next Earnings (Estimated): 8/12/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Instruments & Supplies
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:TCHBF
• CIK: N/A
• Web: www.tecan.com
• Phone: (144) 922-8888
• Fax: N/A
• Employees: 3,315
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 49.62
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A